



**Scientist/Associate Scientist, Cancer Immunotherapy  
Job Code 280CC**

**General Summary:**

Fate Therapeutics is currently seeking a skilled and motivated cell biologist to support the company's Cancer Immunotherapy programs. The successful candidate will join a multidisciplinary team pursuing the development and characterization of next generation engineered T and CAR-T cells from gene edited induced pluripotent stem cells (iPSCs) for the development of off-the-shelf immunotherapies.

The candidate must have good knowledge of cell biology with emphasis on T cell biology and immunology. The candidate will perform, optimize and analyze experiments involving the in vitro differentiation of iPSC towards the T lymphoid lineage. Primary responsibilities will include the derivation and characterization of novel platforms to generate functional subsets of T lymphocytes from iPSCs, including the planning and execution of functional assays and the support of downstream application groups. This position will require independent research as well as coordination with the molecular biology, cellular engineering and process development groups.

This is a full-time position reporting to a Lead Scientist, Cancer Immunotherapy and is located at our corporate headquarters in San Diego, CA.

**Responsibilities:**

- Lead certain aspects of developing novel protocols and employing unique strategies to generate large number of engineered T lymphocytes
- Investigate various strategies in the derivation of engineered T lymphocytes from stem cells, including pluripotent stem cells
- Study various strategies to enhance T cell function and skew T cell lineage differentiation
- Conduct routine and develop novel immune cells functional assay, e.g., proliferation, activation/stimulation, cytokine release, in vitro and in vivo killing assays
- Conduct routine and develop novel cellular characterization strategies including flow cytometry, microscopy, automated cell counting, immunofluorescence and molecular analysis including RNA-seq
- Participate in daily laboratory maintenance activities including ordering and maintaining stocks of lab reagents and samples

**Qualifications:**

- PhD degree in Cell Biology, Developmental Biology, Immunology or other related fields with a minimum 2+ years of laboratory experience in clinical or biopharmaceutical setting or M.S. degree with a minimum 5+ years relevant lab experience, or a B.S. degree with a minimum of 8+ years of relevant lab experience
- Proven track record in immunology, T cell development and oncology
- Preference for previous preclinical experience in T cell or NK cell therapy
- Experience with CAR-T cells is a plus



- Prior (min 3-5 years) experience and extensive knowledge in aseptic cell culture techniques is a requirement
- Prior experience with flow cytometry data acquisition and analysis is a requirement
- Excellent communication, record keeping and data analysis skills

#### **Working Conditions and Physical Requirements**

- Will require working with cells and cell lines of human and/or animal origin
- Occasional evening and weekend work will be required
- 100% on-site work at corporate headquarters in San Diego, CA

The preceding job description indicates the general nature and level of work performed by employees within this classification. Additional and incidental duties related to the primary duties may be required from time to time.

For consideration send cover letter and curriculum vitae to: [careers@fatetherapeutics.com](mailto:careers@fatetherapeutics.com) and reference job 280CC.

#### **About Fate Therapeutics, Inc.**

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company's immuno-oncology pipeline is comprised of universal, off-the-shelf NK cell and T-cell product candidates that are mass produced using its industry-leading induced pluripotent stem cell (iPSC) product platform. In 2019, Fate Therapeutics initiated the first-ever clinical trial in the United States of an iPSC-derived cell product, and is developing this NK cell cancer immunotherapy, FT500, for the treatment of patients with advanced solid tumors and lymphomas that are resistant to checkpoint inhibitor therapy. The Company is also developing FT516, an engineered iPSC-derived NK cell product candidate incorporating a novel high-affinity, non-cleavable 158V CD16 Fc receptor for enhanced binding to monoclonal antibodies, and is advancing a highly-differentiated pipeline of iPSC-derived chimeric antigen receptor (CAR) NK cell and T-cell product candidates designed to simultaneously engage multiple tumor-associated antigens for the treatment of hematologic malignancies and solid tumors. The Company's immuno-regulatory pipeline includes ProTmune™, a pharmacologically-modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of acute graft-versus-host disease (GvHD), and an iPSC-derived myeloid-derived suppressor cell (MDSC) immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit [www.fatetherapeutics.com](http://www.fatetherapeutics.com).